TGFβ: the molecular Jekyll and Hyde of cancer (original) (raw)

• Siegel, P. M. & Massague, J. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nature Rev. Cancer 3, 807–821 (2003).
  Article CAS Google Scholar
• Derynck, R. & Zhang, Y. E. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425, 577–584 (2003).
  Article CAS PubMed Google Scholar
• Bierie, B. & Moses, H. L. TGF-β and cancer. Cytokine Growth Factor Rev 17, 29–40 (2006).
  Article CAS PubMed Google Scholar
• Lin, H. Y., Wang, X. F., Ng-Eaton, E., Weinberg, R. A. & Lodish, H. F. Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase. Cell 68, 775–785 (1992). Describes the initial cloning and characterization of the type II TGFβ receptor. The binding affinity of TGFβ1 and TGFβ2 was shown, along with an analysis of this receptor as a functional serine and threonine kinase.
  Article CAS PubMed Google Scholar
• Wang, X. F. et al. Expression cloning and characterization of the TGF-β type III receptor. Cell 67, 797–805 (1991). Describes the initial cloning and characterization of a type III TGFβ receptor. It was shown that the cloned type III receptor was able to bind TGFβ1 and increase the ligand affinity for the type II TGFβ receptor.
  Article CAS PubMed Google Scholar
• Yu, Q. & Stamenkovic, I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev. 14, 163–176 (2000).
  PubMed PubMed Central Google Scholar
• Munger, J. S. et al. The integrin-α v β 6 binds and activates latent TGF β 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96, 319–328 (1999).
  Article CAS PubMed Google Scholar
• Lin, H. Y. et al. The soluble exoplasmic domain of the type II transforming growth factor (TGF)-β receptor. A heterogeneously glycosylated protein with high affinity and selectivity for TGF-β ligands. J. Biol. Chem. 270, 2747–2754 (1995).
  Article CAS PubMed Google Scholar
• Crawford, S. E. et al. Thrombospondin-1 is a major activator of TGF-β1 in vivo. Cell 93, 1159–1170 (1998).
  Article CAS PubMed Google Scholar
• Moustakas, A. et al. The transforming growth factor-β receptors types I, II, and III form hetero-oligomeric complexes in the presence of ligand. J. Biol. Chem. 268, 22215–22218 (1993).
  CAS PubMed Google Scholar
• Gilboa, L., Wells, R. G., Lodish, H. F. & Henis, Y. I. Oligomeric structure of type I and type II transforming growth factor-β receptors: homodimers form in the ER and persist at the plasma membrane. J. Cell. Biol. 140, 767–777 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Goumans, M. J. et al. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFβ/ALK5 signaling. Mol. Cell 12, 817–828 (2003).
  Article CAS PubMed Google Scholar
• Wrana, J. L. et al. TGF β signals through a heteromeric protein kinase receptor complex. Cell 71, 1003–1014 (1992).
  Article CAS PubMed Google Scholar
• Luo, K. & Lodish, H. F. Signaling by chimeric erythropoietin-TGF-β receptors: homodimerization of the cytoplasmic domain of the type I TGF-β receptor and heterodimerization with the type II receptor are both required for intracellular signal transduction. EMBO J. 15, 4485–4496 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Feng, X. H. & Derynck, R. Ligand-independent activation of transforming growth factor (TGF) β signaling pathways by heteromeric cytoplasmic domains of TGF-β receptors. J. Biol. Chem. 271, 13123–13129 (1996).
  Article CAS PubMed Google Scholar
• Olivey, H. E., Mundell, N. A., Austin, A. F. & Barnett, J. V. Transforming growth factor-β stimulates epithelial-mesenchymal transformation in the proepicardium. Dev. Dyn. 235, 50–59 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Shi, Y. & Massague, J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113, 685–700 (2003).
  Article CAS PubMed Google Scholar
• Moustakas, A. & Heldin, C. H. Non-Smad TGF-β signals. J. Cell Sci. 118, 3573–3584 (2005).
  Article CAS PubMed Google Scholar
• Barrios-Rodiles, M. et al. High-throughput mapping of a dynamic signaling network in mammalian cells. Science 307, 1621–1625 (2005). The TGFβ pathway has been targeted for interactome mapping. This paper and supplementary material outlines the results from approximately 12,000 individual experimental reactions that resulted in the identification of a large number of new interactions.
  Article CAS PubMed Google Scholar
• Feng, X. H. & Derynck, R. Specificity and versatility in tgf-β signaling through Smads. Annu. Rev. Cell Dev. Biol. 21, 659–693 (2005).
  Article CAS PubMed Google Scholar
• Massague, J. How cells read TGF-β signals. Nature Rev. Mol. Cell Biol. 1, 169–178 (2000).
  Article CAS Google Scholar
• Akhurst, R. J. & Derynck, R. TGF-β signaling in cancer-a double-edged sword. Trends Cell Biol. 11, S44–S51 (2001).
  CAS PubMed Google Scholar
• Derynck, R., Akhurst, R. J. & Balmain, A. TGF-β signaling in tumor suppression and cancer progression. Nature Genet. 29, 117–129 (2001).
  Article CAS PubMed Google Scholar
• Lin, H. K., Bergmann, S. & Pandolfi, P. P. Cytoplasmic PML function in TGF-β signalling. Nature 431, 205–211 (2004).
  Article CAS PubMed Google Scholar
• Zhang, L. et al. A role for MEK kinase 1 in TGF-β/activin-induced epithelium movement and embryonic eyelid closure. EMBO J. 22, 4443–4454 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Chiu, C. et al. TGF-β-induced p38 activation is mediated by Rac1-regulated generation of reactive oxygen species in cultured human keratinocytes. Int. J. Mol. Med. 8, 251–255 (2001).
  CAS PubMed Google Scholar
• Edlund, S., Landstrom, M., Heldin, C. H. & Aspenstrom, P. Smad7 is required for TGF-β-induced activation of the small GTPase Cdc42. J. Cell Sci. 117, 1835–1847 (2004).
  Article CAS PubMed Google Scholar
• Perlman, R., Schiemann, W. P., Brooks, M. W., Lodish, H. F. & Weinberg, R. A. TGF-β-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation. Nature Cell Biol. 3, 708–714 (2001).
  Article CAS PubMed Google Scholar
• Wilkes, M. C., Murphy, S. J., Garamszegi, N. & Leof, E. B. Cell-type-specific activation of PAK2 by transforming growth factor-β independent of Smad2 and Smad3. Mol. Cell Biol. 23, 8878–8889 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Mulder, K. M. & Morris, S. L. Activation of p21ras by transforming growth factor-β in epithelial cells. J. Biol. Chem. 267, 5029–5031 (1992).
  CAS PubMed Google Scholar
• Yi, J. Y., Shin, I. & Arteaga, C. L. Type I transforming growth factor-β receptor binds to and activates phosphatidylinositol 3-kinase. J. Biol. Chem. 280, 10870–10876 (2005).
  Article CAS PubMed Google Scholar
• Ozdamar, B. et al. Regulation of the polarity protein Par6 by TGFβ receptors controls epithelial cell plasticity. Science 307, 1603–1609 (2005).
  Article CAS PubMed Google Scholar
• Bhowmick, N. A. et al. Transforming growth factor-β1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol. Biol. Cell 12, 27–36 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Shibuya, H. et al. TAB1: an activator of the TAK1 MAPKKK in TGF-β signal transduction. Science 272, 1179–1182 (1996).
  Article CAS PubMed Google Scholar
• Yamaguchi, K. et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction. Science 270, 2008–2011 (1995).
  Article CAS PubMed Google Scholar
• Petritsch, C., Beug, H., Balmain, A. & Oft, M. TGF-β inhibits p70 S6 kinase via protein phosphatase 2A to induce G(1) arrest. Genes Dev. 14, 3093–3101 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Levy, L. & Hill, C. S. Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev. 17, 41–58 (2006).
  Article CAS PubMed Google Scholar
• Markowitz, S. et al. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 268, 1336–1338 (1995). This is the first conclusive study that links inactivation of the type II TGFβ receptor to cancer.
  Article CAS PubMed Google Scholar
• Grady, W. M. Genomic instability and colon cancer. Cancer Metastasis Rev. 23, 11–27 (2004).
  Article CAS PubMed Google Scholar
• Pasche, B. Role of transforming growth factor-β in cancer. J. Cell. Physiol. 186, 153–168 (2001).
  Article CAS PubMed Google Scholar
• Bacon, A. L., Farrington, S. M. & Dunlop, M. G. Mutation frequency in coding and non-coding repeat sequences in mismatch repair deficient cells derived from normal human tissue. Oncogene 20, 7464–7471 (2001).
  Article CAS PubMed Google Scholar
• Kim, S. J., Im, Y. H., Markowitz, S. D. & Bang, Y. J. Molecular mechanisms of inactivation of TGF-β receptors during carcinogenesis. Cytokine Growth Factor Rev. 11, 159–168 (2000).
  Article CAS PubMed Google Scholar
• Kang, S. H. et al. Transcriptional repression of the transforming growth factor-β type I receptor gene by DNA methylation results in the development of TGF-β resistance in human gastric cancer. Oncogene 18, 7280–7286 (1999).
  Article CAS PubMed Google Scholar
• Lebrin, F., Deckers, M., Bertolino, P. & Ten Dijke, P. TGF-β receptor function in the endothelium. Cardiovasc Res. 65, 599–608 (2005).
  Article CAS PubMed Google Scholar
• Pangas, S. A. & Matzuk, M. M. Genetic models for transforming growth factor-β superfamily signaling in ovarian follicle development. Mol. Cell. Endocrinol. 225, 83–91 (2004).
  Article CAS PubMed Google Scholar
• Guy, C. T. et al. Expression of the neu proto-oncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl Acad. Sci. USA 89, 10578–10582 (1992).
  Article CAS PubMed PubMed Central Google Scholar
• Guy, C. T., Cardiff, R. D. & Muller, W. J. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell Biol. 12, 954–961 (1992).
  Article CAS PubMed PubMed Central Google Scholar
• Matsui, Y., Halter, S. A., Holt, J. T., Hogan, B. L. & Coffey, R. J. Development of mammary hyperplasia and neoplasia in MMTV-TGF-α transgenic mice. Cell 61, 1147–1155 (1990).
  Article CAS PubMed Google Scholar
• Hennighausen, L. & Robinson, G. W. Information networks in the mammary gland. Nature Rev. Mol. Cell Biol. 6, 715–725 (2005).
  Article CAS Google Scholar
• Shackleton, M. et al. Generation of a functional mammary gland from a single stem cell. Nature 439, 84–88 (2006). Although it is not directly related to TGFβ signalling in cancer, this high-impact paper outlines a new method whereby a single mammary stem cell can be isolated that is able to produce myoepithelium, ductal and alveolar epithelium. A single cell from this population was able to reconstitute all the epithelial and myoepithelial cell types necessary to reconstitute a functional mammary gland when transplanted into a cleared mammary fat pad.
  Article CAS PubMed Google Scholar
• Joseph, H., Gorska, A. E., Sohn, P., Moses, H. L. & Serra, R. Overexpression of a kinase-deficient transforming growth factor-β type II receptor in mouse mammary stroma results in increased epithelial branching. Mol. Biol. Cell 10, 1221–1234 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Nguyen, A. V. & Pollard, J. W. Transforming growth factor β3 induces cell death during the first stage of mammary gland involution. Development 127, 3107–3118 (2000).
  CAS PubMed Google Scholar
• Pierce, D. F., Jr. et al. Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-β 1. Genes Dev. 7, 2308–2317 (1993).
  Article CAS PubMed Google Scholar
• Boulanger, C. A. & Smith, G. H. Reducing mammary cancer risk through premature stem cell senescence. Oncogene 20, 2264–2272 (2001).
  Article CAS PubMed Google Scholar
• Boulanger, C. A., Wagner, K. U. & Smith, G. H. Parity-induced mouse mammary epithelial cells are pluripotent, self-renewing and sensitive to TGF-β1 expression. Oncogene 24, 552–560 (2005).
  Article CAS PubMed Google Scholar
• Jhappan, C. et al. Targeting expression of a transforming growth factor β 1 transgene to the pregnant mammary gland inhibits alveolar development and lactation. EMBO J. 12, 1835–1845 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• Kordon, E. C. et al. Ectopic TGF-β1 expression in the secretory mammary epithelium induces early senescence of the epithelial stem cell population. Dev. Biol. 168, 47–61 (1995).
  Article CAS PubMed Google Scholar
• Pierce, D. F., Jr. et al. Mammary tumor suppression by transforming growth factor-β1 transgene expression. Proc. Natl Acad. Sci. USA 92, 4254–4258 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Muraoka, R. S. et al. Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor β1. Mol. Cell. Biol. 23, 8691–8703 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Muraoka-Cook, R. S. et al. Conditional overexpression of active transforming growth factor β1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Res. 64, 9002–9011 (2004).
  Article CAS PubMed Google Scholar
• Gorska, A. E. et al. Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-β receptor exhibit impaired mammary development and enhanced mammary tumor formation. Am. J. Pathol. 163, 1539–1549 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Lenferink, A. E., Magoon, J., Pepin, M. C., Guimond, A. & O'Connor-McCourt, M. D. Expression of TGF-β type II receptor antisense RNA impairs TGF-β signaling in vitro and promotes mammary gland differentiation in vivo. Int. J. Cancer 107, 919–928 (2003).
  Article CAS PubMed Google Scholar
• Muraoka, R. S. et al. Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 109, 1551–1559 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Forrester, E. et al. Effect of conditional knockout of the type II TGF-β receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res. 65, 2296–2302 (2005). Outlined for the first time the effect of complete conditional type II TGFβ receptor ablation in the context of mammary development and tumourigenesis.
  Article CAS PubMed Google Scholar
• Ewan, K. B. et al. Latent transforming growth factor-β activation in mammary gland: regulation by ovarian hormones affects ductal and alveolar proliferation. Am. J. Pathol. 160, 2081–2093 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Ewan, K. B. et al. Proliferation of estrogen receptor-α-positive mammary epithelial cells is restrained by transforming growth factor-β1 in adult mice. Am. J. Pathol. 167, 409–417 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Tang, B. et al. TGF-β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J. Clin. Invest. 112, 1116–1124 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Muraoka-Cook, R. S. et al. Activated type I TGFβ receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene (2005).
• Oft, M., Heider, K. H. & Beug, H. TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis. Curr. Biol. 8, 1243–1252 (1998).
  Article CAS PubMed Google Scholar
• Siegel, P. M., Shu, W., Cardiff, R. D., Muller, W. J. & Massague, J. Transforming growth factor β signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc. Natl Acad. Sci. USA 100, 8430–8435 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Deckers, M. et al. The tumor suppressor Smad4 is required for transforming growth factor-β-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res. 66, 2202–2209 (2006).
  Article CAS PubMed Google Scholar
• Cui, W. et al. TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86, 531–542 (1996).
  Article CAS PubMed Google Scholar
• Fowlis, D. J., Cui, W., Johnson, S. A., Balmain, A. & Akhurst, R. J. Altered epidermal cell growth control in vivo by inducible expression of transforming growth factor β 1 in the skin of transgenic mice. Cell Growth Differ. 7, 679–687 (1996).
  CAS PubMed Google Scholar
• Cui, W. et al. Concerted action of TGF-β1 and its type II receptor in control of epidermal homeostasis in transgenic mice. Genes Dev. 9, 945–955 (1995).
  Article CAS PubMed Google Scholar
• Amendt, C., Schirmacher, P., Weber, H. & Blessing, M. Expression of a dominant negative type II TGF-β receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development. Oncogene 17, 25–34 (1998).
  Article CAS PubMed Google Scholar
• Go, C. et al. Aberrant cell cycle progression contributes to the early-stage accelerated carcinogenesis in transgenic epidermis expressing the dominant negative TGFβRII. Oncogene 19, 3623–3631 (2000).
  Article CAS PubMed Google Scholar
• Go, C., Li, P. & Wang, X. J. Blocking transforming growth factor-β signaling in transgenic epidermis accelerates chemical carcinogenesis: a mechanism associated with increased angiogenesis. Cancer Res. 59, 2861–2868 (1999).
  CAS PubMed Google Scholar
• Wang, X. J., Liefer, K. M., Tsai, S., O'Malley, B. W. & Roop, D. R. Development of gene-switch transgenic mice that inducibly express transforming growth factor β1 in the epidermis. Proc. Natl Acad. Sci. USA 96, 8483–8488 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Weeks, B. H., He, W., Olson, K. L. & Wang, X. J. Inducible expression of transforming growth factor β1 in papillomas causes rapid metastasis. Cancer Res. 61, 7435–7443 (2001).
  CAS PubMed Google Scholar
• Han, G. et al. Distinct mechanisms of TGF-β1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis. J. Clin. Invest. 115, 1714–1723 (2005). Showed the effect of increased TGFβ expression with the concurrent expression of a dominant-negative type II receptor in the skin epithelium during carcinogenesis. The data show that the expression of TGFβ with a reduction in the tumour-cell-autonomous response to this pathway promotes progression to metastasis.
  Article CAS PubMed PubMed Central Google Scholar
• Wang, X. J. et al. Expression of a dominant-negative type II transforming growth factor-β (TGF-β) receptor in the epidermis of transgenic mice blocks TGF-β-mediated growth inhibition. Proc. Natl Acad. Sci. USA 94, 2386–2391 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Bhowmick, N. A. et al. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303, 848–851 (2004). Showed that TGFβ signalling in some fibroblast subpopulations can regulate the initiation of carcinoma in adjacent epithelia.
  Article CAS PubMed Google Scholar
• Cheng, N. et al. Loss of TGF-β type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-α-, MSP- and HGF-mediated signaling networks. Oncogene 24, 5053–5068 (2005). Showed that TGFβ signalling in fibroblasts can regulate tumour progression in adjacent epithelium through distinct molecular mechanisms.
  Article CAS PubMed PubMed Central Google Scholar
• Hayward, S. W. et al. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res. 61, 8135–8142 (2001).
  CAS PubMed Google Scholar
• Barcellos-Hoff, M. H. & Ravani, S. A. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. 60, 1254–1260 (2000).
  CAS PubMed Google Scholar
• Chang, H. Y. et al. Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc. Natl Acad. Sci. USA 99, 12877–12882 (2002). Showed that fibroblasts isolated from different parts of the body have distinct molecular profiles. The unique molecular identity of each fibroblast subpopulation was used to accurately identify the tissue from which it was derived.
  Article CAS PubMed PubMed Central Google Scholar
• Giannouli, C. C. & Kletsas, D. TGF-β regulates differentially the proliferation of fetal and adult human skin fibroblasts via the activation of PKA and the autocrine action of FGF-2. Cell. Signal. 14 Dec 2005 [epub ahead of print].
• Chen, W. & Wahl, S. M. TGF-β: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression. Cytokine Growth Factor Rev. 14, 85–89 (2003).
  Article CAS PubMed Google Scholar
• de Visser, K. E. & Kast, W. M. Effects of TGF-β on the immune system: implications for cancer immunotherapy. Leukemia 13, 1188–1199 (1999).
  Article CAS PubMed Google Scholar
• Gorelik, L. & Flavell, R. A. Transforming growth factor-β in T-cell biology. Nature Rev. Immunol. 2, 46–53 (2002).
  Article CAS Google Scholar
• Wahl, S. M., Swisher, J., McCartney-Francis, N. & Chen, W. TGF-β: the perpetrator of immune suppression by regulatory T cells and suicidal T cells. J. Leukoc. Biol. 76, 15–24 (2004).
  Article CAS PubMed Google Scholar
• Goumans, M. J., Lebrin, F. & Valdimarsdottir, G. Controlling the angiogenic switch: a balance between two distinct TGF-β receptor signaling pathways. Trends Cardiovasc. Med. 13, 301–307 (2003).
  Article CAS PubMed Google Scholar
• Muraoka-Cook, R. S., Dumont, N. & Arteaga, C. L. Dual role of transforming growth factor β in mammary tumorigenesis and metastatic progression. Clin. Cancer Res. 11, 937s–943s (2005).
  CAS PubMed Google Scholar
• Gorelik, L. & Flavell, R. A. Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12, 171–181 (2000).
  Article CAS PubMed Google Scholar
• Kulkarni, A. B. et al. Transforming growth factor-β1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl Acad. Sci. USA 90, 770–774 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• Leveen, P. et al. Induced disruption of the transforming growth factor-β type II receptor gene in mice causes a lethal inflammatory disorder that is transplantable. Blood 100, 560–568 (2002).
  Article CAS PubMed Google Scholar
• Shull, M. M. et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 359, 693–699 (1992).
  Article CAS PubMed PubMed Central Google Scholar
• Ruzek, M. C. et al. Minimal effects on immune parameters following chronic anti-TGF-β monoclonal antibody administration to normal mice. Immunopharmacol. Immunotoxicol. 25, 235–257 (2003).
  Article CAS PubMed Google Scholar
• Yang, Y. A. et al. Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. 109, 1607–1615 (2002). Before this study it was not known if the systemic inhibition of TGFβ signalling would be a viable strategy for administration over a sustained duration in vivo . However, this report indicates that in mice, a sustained systemic inhibition of TGFβ does not result in any observed adverse effects.
  Article CAS PubMed PubMed Central Google Scholar
• Yingling, J. M., Blanchard, K. L. & Sawyer, J. S. Development of TGF-β signalling inhibitors for cancer therapy. Nature Rev. Drug Discov. 3, 1011–1022 (2004).
  Article CAS Google Scholar
• Smyth, M. J. et al. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J. Immunol. 176, 1582–1587 (2006).
  Article CAS PubMed Google Scholar
• Fontana, A., Constam, D. B., Frei, K., Malipiero, U. & Pfister, H. W. Modulation of the immune response by transforming growth factor-β. Int. Arch. Allergy Immunol. 99, 1–7 (1992).
  Article CAS PubMed Google Scholar
• Fontana, A., Bodmer, S., Frei, K., Malipiero, U. & Siepl, C. Expression of TGF-β2 in human glioblastoma: a role in resistance to immune rejection? Ciba Found. Symp. 157, 232–238; discussion 238–241 (1991).
  CAS PubMed Google Scholar
• Gorelik, L. & Flavell, R. A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nature Med. 7, 1118–1122 (2001). Blockade of TGFβ signalling in T cells resulted in a marked resistance to cancer when mice were challenged with live tumour cells. The resistance was shown to be the result of an efficient eradication of tumour cells owing to a robust immune response after the attenuation of TGFβ signalling in T cells.
  Article CAS PubMed Google Scholar
• Thomas, D. A. & Massague, J. TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8, 369–380 (2005).
  Article CAS PubMed Google Scholar
• Zhang, Q. et al. Adoptive transfer of tumor-reactive transforming growth factor-β-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res. 65, 1761–1769 (2005).
  Article CAS PubMed Google Scholar
• Peng, S. B. et al. Kinetic characterization of novel pyrazole TGF-β receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition. Biochemistry 44, 2293–2304 (2005).
  Article CAS PubMed Google Scholar
• Tojo, M. et al. The ALK-5 inhibitor A-83–01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-β. Cancer Sci. 96, 791–800 (2005).
  Article CAS PubMed Google Scholar
• Ge, R. et al. Selective inhibitors of type I receptor kinase block cellular transforming growth factor-β signaling. Biochem. Pharmacol. 68, 41–50 (2004).
  Article CAS PubMed Google Scholar
• DaCosta Byfield, S., Major, C., Laping, N. J. & Roberts, A. B. SB-505124 is a selective inhibitor of transforming growth factor-β type I receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 65, 744–752 (2004).
  Article PubMed Google Scholar
• Uhl, M. et al. SD-208, a novel transforming growth factor-β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 64, 7954–7961 (2004).
  Article CAS PubMed Google Scholar
• Inman, G. J. et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 62, 65–74 (2002).
  Article CAS PubMed Google Scholar
• Landis, M. D., Seachrist, D. D., Montanez-Wiscovich, M. E., Danielpour, D. & Keri, R. A. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-β signaling in ErbB2/Neu-induced tumors from transgenic mice. Oncogene 24, 5173–5190 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Yoshinaga, K. et al. Clinical significance of the expression of activin A in esophageal carcinoma. Int. J. Oncol. 22, 75–80 (2003).
  CAS PubMed Google Scholar
• Subramanian, G. et al. Targeting endogenous transforming growth factor-β receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1. Cancer Res. 64, 5200–5211 (2004).
  Article CAS PubMed Google Scholar
• Cosgrove, D. et al. Integrin α1β1 and transforming growth factor-β1 play distinct roles in alport glomerular pathogenesis and serve as dual targets for metabolic therapy. Am. J. Pathol. 157, 1649–1659 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Bandyopadhyay, A. et al. A soluble transforming growth factor β type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells. Cancer Res. 59, 5041–5046 (1999).
  CAS PubMed Google Scholar
• Bandyopadhyay, A. et al. Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. Cancer Res. 62, 4690–4695 (2002).
  CAS PubMed Google Scholar
• Dasch, J. R., Pace, D. R., Waegell, W., Inenaga, D. & Ellingsworth, L. Monoclonal antibodies recognizing transforming growth factor-β. Bioactivity neutralization and transforming growth factor-β 2 affinity purification. J. Immunol. 142, 1536–1541 (1989).
  CAS PubMed Google Scholar
• Cordeiro, M. F., Gay, J. A. & Khaw, P. T. Human anti-transforming growth factor-β2 antibody: a new glaucoma anti-scarring agent. Invest. Ophthalmol. Vis. Sci. 40, 2225–2234 (1999).
  CAS PubMed Google Scholar
• Thompson, J. E. et al. A fully human antibody neutralising biologically active human TGFβ2 for use in therapy. J. Immunol. Methods 227, 17–29 (1999).
  Article CAS PubMed Google Scholar
• Lucas, C. et al. The autocrine production of transforming growth factor-β1 during lymphocyte activation. A study with a monoclonal antibody-based ELISA. J. Immunol. 145, 1415–1422 (1990).
  CAS PubMed Google Scholar
• Arteaga, C. L., Carty-Dugger, T., Moses, H. L., Hurd, S. D. & Pietenpol, J. A. Transforming growth factor β1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ. 4, 193–201 (1993).
  CAS PubMed Google Scholar
• Arteaga, C. L., Dugger, T. C., Winnier, A. R. & Forbes, J. T. Evidence for a positive role of transforming growth factor-β in human breast cancer cell tumorigenesis. J. Cell. Biochem. Suppl. 17G, 187–193 (1993).
  Article CAS PubMed Google Scholar
• Arteaga, C. L. et al. Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-β interactions in human breast cancer progression. J. Clin. Invest. 92, 2569–2576 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• Fakhrai, H. et al. Eradication of established intracranial rat gliomas by transforming growth factor-β antisense gene therapy. Proc. Natl Acad. Sci. USA 93, 2909–2914 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Liau, L. M., Fakhrai, H. & Black, K. L. Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-β antisense gene. Neurol. Res. 20, 742–747 (1998).
  Article CAS PubMed Google Scholar
• Schlingensiepen, K. H. et al. Targeted tumor therapy with the TGF-β2 antisense compound AP 12009. Cytokine Growth Factor Rev. 17, 729–139 (2005).
  Google Scholar
• Schlingensiepen, R. et al. Intracerebral and intrathecal infusion of the TGF-β2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety. Oligonucleotides 15, 94–104 (2005).
  Article CAS PubMed Google Scholar
• Rajagopalan, H., Nowak, M. A., Vogelstein, B. & Lengauer, C. The significance of unstable chromosomes in colorectal cancer. Nature Rev. Cancer 3, 695–701 (2003).
  Article CAS Google Scholar
• Vogelstein, B. & Kinzler, K. W. Cancer genes and the pathways they control. Nature Med. 10, 789–799 (2004).
  Article CAS PubMed Google Scholar
• Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
  Article CAS PubMed Google Scholar
• Hill, R., Song, Y., Cardiff, R. D. & Van Dyke, T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 123, 1001–1011 (2005).
  Article CAS PubMed Google Scholar
• Desgrosellier, J. S., Mundell, N. A., McDonnell, M. A., Moses, H. L. & Barnett, J. V. Activin receptor-like kinase 2 and Smad6 regulate epithelial-mesenchymal transformation during cardiac valve formation. Dev. Biol. 280, 201–210 (2005).
  Article CAS PubMed Google Scholar
• Lai, Y. T. et al. Activin receptor-like kinase 2 can mediate atrioventricular cushion transformation. Dev. Biol. 222, 1–11 (2000).
  Article CAS PubMed Google Scholar
• Miettinen, P. J., Ebner, R., Lopez, A. R. & Derynck, R. TGF-β induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J. Cell Biol. 127, 2021–2036 (1994).
  Article CAS PubMed Google Scholar
• Adams, D. H. et al. Transforming growth factor-β induces human T lymphocyte migration in vitro. J. Immunol. 147, 609–6012 (1991).
  CAS PubMed Google Scholar
• Ahmadzadeh, M. & Rosenberg, S. A. TGF-β1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J. Immunol. 174, 5215–5223 (2005).
  Article CAS PubMed Google Scholar
• Bogdan, C. & Nathan, C. Modulation of macrophage function by transforming growth factor β, interleukin-4, and interleukin-10. Ann. NY Acad. Sci. 685, 713–739 (1993).
  Article CAS PubMed Google Scholar
• Wahl, S. M. et al. Transforming growth factor-β is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. J. Immunol. 140, 3026–3032 (1988).
  CAS PubMed Google Scholar
• Bombara, C. & Ignotz, R. A. TGF-β inhibits proliferation of and promotes differentiation of human promonocytic leukemia cells. J. Cell. Physiol. 153, 30–37 (1992).
  Article CAS PubMed Google Scholar
• Kitamura, M. Identification of an inhibitor targeting macrophage production of monocyte chemoattractant protein-1 as TGF-β 1. J. Immunol. 159, 1404–1411 (1997).
  CAS PubMed Google Scholar
• Feinberg, M. W. et al. Essential role for Smad3 in regulating MCP-1 expression and vascular inflammation. Circ. Res. 94, 601–608 (2004).
  Article CAS PubMed Google Scholar
• Fadok, V. A. et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-β, PGE2, and PAF. J. Clin. Invest. 101, 890–898 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• McDonald, P. P., Fadok, V. A., Bratton, D. & Henson, P. M. Transcriptional and translational regulation of inflammatory mediator production by endogenous TGF-β in macrophages that have ingested apoptotic cells. J. Immunol. 163, 6164–6172 (1999).
  CAS PubMed Google Scholar
• Xiao, Y. Q. et al. Cross-talk between ERK and p38 MAPK mediates selective suppression of pro-inflammatory cytokines by transforming growth factor-β. J. Biol. Chem. 277, 14884–14893 (2002).
  Article CAS PubMed Google Scholar
• Wang, J. et al. Role of tyrosine phosphorylation in ligand-independent sequestration of CXCR4 in human primary monocytes-macrophages. J. Biol. Chem. 276, 49236–49243 (2001).
  Article CAS PubMed Google Scholar
• Franitza, S. et al. TGF-β1 enhances SDF-1α-induced chemotaxis and homing of naive T cells by up-regulating CXCR4 expression and downstream cytoskeletal effector molecules. Eur. J. Immunol. 32, 193–202 (2002).
  Article CAS PubMed Google Scholar
• Orimo, A. et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335–348 (2005).
  Article CAS PubMed Google Scholar
• Geiser, A. G. et al. Transforming growth factor β1 (TGF-β1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-β1 null mouse phenotype. Proc. Natl Acad. Sci. USA 90, 9944–9948 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• Lee, Y. J. et al. TGF-β suppresses IFN-γ induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression. J. Immunol. 158, 2065–2075 (1997).
  CAS PubMed Google Scholar
• Johns, L. D. et al. Transforming growth factor-β 1 differentially regulates proliferation and MHC class-II antigen expression in forebrain and brainstem astrocyte primary cultures. Brain Res. 585, 229–236 (1992).
  Article CAS PubMed Google Scholar
• Ma, D. & Niederkorn, J. Y. Transforming growth factor-β down-regulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis. Immunology 86, 263–269 (1995).
  CAS PubMed PubMed Central Google Scholar
• Witham, T. F. et al. Expression of a soluble transforming growth factor-β (TGFβ) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo. J. Neurooncol. 64, 63–69 (2003).
  PubMed Google Scholar
• Reibman, J. et al. Transforming growth factor β1, a potent chemoattractant for human neutrophils, bypasses classic signal-transduction pathways. Proc. Natl Acad. Sci. USA 88, 6805–6809 (1991).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, J. J., Sun, Y. & Nabel, G. J. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 282, 1714–1717 (1998).
  Article CAS PubMed Google Scholar
• Hahne, M. et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274, 1363–1366 (1996).
  Article CAS PubMed Google Scholar